Drug Trial Radar · NCT05789056
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Mar 14, 2023
Primary completion
Dec 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- Quoin PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Conditions
- Netherton Syndrome
Interventions
QRX003, 4% LotionDrug
QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with 1-point reduction on IGATime frame: Up to week 16
- Proportion of subjects with 2-point reduction on IGATime frame: Up to week 16
- NS surface area changeTime frame: Up to week 16
- WI-NRS score changeTime frame: Up to week 16
- Assessment of subject satisfaction with treatment based on TSQMTime frame: Up to week 16
- Proportion of subjects requiring rescue therapyTime frame: Up to week 16
- Safety Assessment-AEsTime frame: Up to week 16
- Safety Assessment-LSRsTime frame: Up to week 16
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site #1
San Diego, California · Recruiting
Site #4
Indianapolis, Indiana · Recruiting
Site #5
Quincy, Massachusetts · Recruiting
Site #2
San Antonio, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.